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The expression of phospholipase D1 (PLD1) and PLD2 were found to decrease at the transcription
level during both replicative and premature senescence in human lung ﬁbroblast IMR-90 cells.
Knockdown of PLD2 dramatically induced senescent phenotype in proliferating IMR-90 cells and
wild-type HCT116 colon cancer cells, whereas this response was nearly abolished in p53- or
p21Cip1/WAF1-null HCT116 cells. PLD2 knockdown increased the intracellular reactive oxygen species
(ROS). Antioxidant N-acetyl-L-cysteine, NADPH oxidase inhibitor apocynin, and p22phox small
interfering RNA (siRNA) reduced ROS generation and thus suppressed the appearance of senescence
markers. Elevated CK2 a subunit (CK2a) expression repressed PLD2 downregulation-mediated
senescence. PLD2 overexpression increased protein kinase CK2 (also known as casein kinase 2)
(CK2) activity. Taken together, these results show that PLD2 downregulation causes senescence
through the p53–p21Cip1/WAF1 pathway by stimulating ROS production, which is induced by CK2
inhibition.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Phospholipase D (PLD) hydrolyzes phosphatidylcholine to
generate the lipidic second messenger, phosphatidic acid (PA)
and free choline. Numerous second messengers have been impli-
cated in a wide range of biological functions including membrane
vesicle trafﬁcking, exocytosis, cell migration, anti-apoptotic signal-
ing, cytoskeletal reorganization, and mitogenesis [1,2]. Two iso-
forms of mammalian PLD, namely, PLD1 and PLD2, have been
reported. They share about 50% amino acid similarity, but exhibit
different regulatory properties. PLD1 (120 kDa) has a low basal
activity and is activated by phosphatidylinositol 4,5-bisphosphate
(PIP2), protein kinase C (PKC), and members of the RhoA
and ADP-ribosylation factor (ARF) families of small G proteins. In
contrast, PLD2 (106 kDa) exhibits a higher basal level of cellularactivity than PLD1, and is less responsive to PKC, RhoA, and ARF.
PLD1 and PLD2 show a diverse subcellular localization. PLD activity
is known to increase in response to mitogenic signals and activated
oncoproteins such as EGF, v-Src, and v-Ras. PLD is also implicated
in cell proliferation and cancer with an upregulation of its activity
and expression in several types of human cancers [3,4]. Various
chromosomal alterations in the PLD gene loci have been found in
the ovarian, lung, breast, esophageal, and prostate cancers [5–7].
Normal primary cells enter an irreversible state of growth arrest
termed ‘‘replicative senescence’’ after a ﬁnite number of cell
divisions [8]. Replicative senescence is primarily driven by telo-
mere shortening, which is recognized as DNA damage in cells. On
the other hand, various forms of stress such as reactive oxygen spe-
cies (ROS) and oncogenic activation induce an acute form of senes-
cence called premature senescence [9–11]. Two tumor suppressor
genes, p53 and Rb, have been implicated in the induction of repli-
cative and premature senescence, called collectively as cellular
senescence. Cellular senescence is also characterized by molecular
and phenotypic characteristics, including the appearance of senes-
cence-associated b-galactosidase activity (SA-b-gal) and the accu-
mulation of p21Cip1/WAF1 [12,13].
It has been shown that a decrease in the PLD activity may be
associated with senescence. The senescence induction with cera-
mide may mediate PLD inactivation by exerting an inhibitory effect
on PLD activators including PKC and RhoA [14–16]. However, the
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progression of PLD-mediated senescence remains unknown. In
the present study, we investigated the physiological signiﬁcance
of PLD2 in the context of cellular senescence. Our results indicate
that not only decreased PLD2 expression at the transcriptional
level parallels with replicative and premature senescence in
human ﬁbroblasts, but also the downregulation of PLD2 induces
senescence via a ROS–p53–p21Cip1/WAF1 pathway.
2. Materials and methods
2.1. Materials
Antibodies against PLD, CK2a, CK2b, p53, p21Cip1/WAF1, p22phox,
and b-actin were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA). Anti-hemagglutinin (HA) antibody was obtained from
Roche (Basel, Switzerland). Rhodamine-conjugated goat anti-rab-
bit IgG, CM-H2DCFDA, and dihydroethidium (DHE) were purchased
from Invitrogen (Carlsbad, CA). CK2 peptide substrate (RRREEE-
TEEE) was synthesized using an automatic synthesizer (Model
431A, Applied Biosystems) and puriﬁed by reverse phase chroma-
tography. [c-32P]ATP was purchased from Amersham Pharmacia
Biotech (Korea).
2.2. Cell culture
Human diploid ﬁbroblast IMR-90 cells were obtained from
ATCC (Manassas, VA) at a population doubling level (PDL) of 24.
IMR-90 cells and HCT116 human colon cancer cells (wild-type,
p53/, and p21/) were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS)
under a humidiﬁed atmosphere of 5% (v/v) CO2 at 37 C. The num-
ber of population doublings (PD) was calculated as PD = log (Nf/Ni)/
log2, where Nf is the ﬁnal cell number and Ni is the initial number
of seeded cells. For premature senescence, the cells were exposed
to multiple concentrations of H2O2 diluted in DMEM containing
10% FBS, for 2 h. The cells were washed with ice-cold phosphate-
buffered saline (PBS) and then provided with fresh medium for
4 days prior to harvest or staining.
2.3. RNA interference and DNA transfections
The PLD2 siRNA, 50-AAGAGGUGGCUGGUGGUGAAGdTdT-30;
CK2 siRNA, 50-UCAAGAUGACUACCAGCUGdTdT-30 and the negative
control siRNA, 50-GCUCAGAUCAAUACGGAGAdTdT-30 were used.
The siRNA for p22phox was obtained from Santa Cruz Biotechnology
(Santa Cruz, CA). Cells were transfected with siRNAs using Lipofect-
amine (Invitrogen, Carlsbad, CA), according to the manufacturer’s
instructions. Five hours after transfection, the medium was
replaced with fresh medium, and the cells were grown for 2 days
before being harvested. To induce overexpression of PLD2 and
CK2a, cells were transfected with pcDNA-PLD2 or pcDNA-CK2a
by Lipofectamine, according to the manufacturer’s instructions.
2.4. Preparation of cell extracts and Western blotting
For the preparation of cell extracts, cells were lysed by sonica-
tion in lysis buffer [50 mM Tris–HCl (pH 8.0), 20 mM NaCl, 1 mM
MgCl2, 1 mM EDTA, 1% Nonidet P-40, 1 mM sodium orthovanadate,
1 mM sodium pyrophosphate, 4 mM p-nitrophenyl phosphate, and
protease inhibitor mix]. The particulate debris was removed by
centrifugation at 12000g, the volume of the supernatants was
adjusted for equal protein concentration, and Western blotting
was performed as described previously [17].2.5. Reverse transcription-PCR (RT-PCR)
Total RNA was extracted from HCT116 cells. RNA was reverse-
transcribed using gene-speciﬁc reverse primers and Reverse
Transcriptase (Takara, Japan), and the resulting cDNA was PCR-
ampliﬁed. The primer sequences used for PCR include: PLD1,
PLD1-Fwd (50-TGCTCTACAGGCAATCATGC-30) and PLD1-Rev (50-G
CACTGTAGCCGAAGTCCTC-30); PLD2, PLD2-Fwd (50-CAGCAGGGAC
TCTGGAGAAC-30) and PLD2-Rev (50-TGAATACTCCCCACGACAC
A-30). Primers for b-actin were used to standardize the concentra-
tion of RNA in each sample. PCR products were resolved on a 1.5%
agarose gel, and quantiﬁcation of the RT-PCR bands was performed
using densitometry.
2.6. Immunocytochemical staining
Cells were seeded on to 4-well micro-chamber slides (Nunc,
Naperville, IL) and ﬁxed using 4% paraformaldehyde in PBS for
10 min at room temperature and then permeabilized in 0.25% Tri-
ton X-100 before blocking with 2% bovine serum albumin in PBS.
The cells were incubated with primary antibodies (anti-PLD2,
1:200) at room temperature for 1 h, followed by incubation with
the secondary rhodamine-conjugated goat anti-rabbit IgG (1:200)
antibody. 40,6-Diamidino-2-phenylindole (DAPI) (Molecular
Probes, Eugene, OR) was used to counterstain the nuclei, and ﬂuo-
rescence signals were detected using a Carl Zeiss Axioplan 2
Microscope.
2.7. Colorimetric PLD activity assay
PLD activity was measured using a PLD activity colorimetric
assay kit (BioVision, Inc., Milpitas, CA) according to the manufac-
turer’s instructions. In this assay, PLD cleaves choline fromphospha-
tidylcholine. The free choline is then oxidized to produce an
intermediate that reacts with PLD probes to generate color (OD
570 nm).
2.8. CK2 activity assay
The standard assay for phosphotransferase activity of CK2 was
conducted in a 30 lL reaction mixture containing 20 mM Tris–
HCl (pH 7.5), 120 mM KCl, 10 mM MgCl2, and 100 lM [c-32P]ATP
in the presence of 1 mM synthetic peptide substrate (RRREEETEEE)
at 30 C. Cell lysates were added to initiate the reaction and incu-
bated for 15 min. The reaction was stopped by the addition of tri-
chloroacetic acid to a ﬁnal concentration of 10%. The mixture was
centrifuged, and then 10 lL of the supernatant was applied to P-81
paper. The paper was washed in 100 mM phosphoric acid, and
radioactivity was measured by scintillation counting.
2.9. Measurement of intracellular reactive oxygen species (ROS) and
SA-b-gal activity
Intracellular ROS and SA-b-gal activity were measured as
described previously [17].
2.10. Statistical analysis
The results are presented as mean ± standard error. Statistical
analysis was performed using SPSS version 11.0 (SPSS Inc., Chicago,
IL). Data were analyzed by one-way ANOVA, and Duncan’s multi-
ple-range test was performed if differences were identiﬁed among
groups at P of <0.05. Statistical difference between two groups was
determined by unpaired Student t-test. A P value of <0.05 was con-
sidered to be statistically signiﬁcant.
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3.1. Reduced expression of PLD1 and PLD2 during replicative and
premature senescence in IMR-90 cells
To determine how the expression patterns of PLD1 and PLD2 are
affected by replicative senescence, we repeatedly passaged IMR-90
cells until a senescence-like state was observed, as evidenced by a
ﬂattened cell morphology and SA-b-gal staining. Western blot
analysis revealed that the expression of PLD1 and PLD2 in senes-
cent cells (PDL 53) was signiﬁcantly reduced in comparison to that
in the proliferating cells (PDL 30) (Fig. 1A). In contrast, the level of
p53 and p21Cip1/WAF1 proteins increased in the senescent cells. We
then examined whether this decrease in the amount of PLD pro-
teins correlated with a decrease at the transcriptional level. RT-
PCR results indicated that the mRNA expression of PLD1 and
PLD2 signiﬁcantly decreased in replicatively senescent cells
(Fig. 1B). Quantiﬁcation of PLD1 and PLD2 protein and mRNA levels
showed that they were reduced by approximately 60% in senescent
cells compared to proliferating cells (Fig. 1A and B). We next exam-
ined if PLD1 and PLD2 expression decreased in H2O2-induced
senescent IMR-90 cells. Four days after exposure to 100–400 lM
H2O2, proliferating IMR-90 cells (PDL 32) exhibited a senescent
phenotype in a dose-dependent manner with a concomitant
decrease in the protein levels of PLD1 and PLD2 (Fig. 1C). The
mRNA expression of PLD1 and PLD2 also decreased in a dose-
dependent manner in H2O2-treated cells (Fig. 1D). Since PLD2 has
a high basal activity in various cells, the present study focused
on the function of PLD2 in senescence. We investigated the intra-
cellular localization of PLD2 in proliferating and senescent IMR-
90 cells using immunocytochemical analysis. DAPI was used to
counterstain the nuclei. While signiﬁcant PLD2 expression wasFig. 1. Decrease in the expression of PLD1 and PLD2 during senescence in IMR-90 cells. (
ﬁxed and stained with 5-bromo-4-chloro-3-indolyl b-D-galactoside as described in Secti
were lysed, subjected to electrophoresis on a 10% (w/v) SDS–polyacrylamide gel, and vi
served as the loading control. (B) Total RNA was extracted from cells and reverse-transc
were resolved on a 1.5% (w/v) agarose gel. (C) IMR-90 cells (PDL 32) were treated with m
medium, the cells were incubated in fresh culture medium for 4 days and stained with 5-
electrophoresis on a 10% (w/v) SDS–polyacrylamide gel, and visualized by Western blott
H2O2-treated cells and reverse-transcribed using PLD1- and PLD2-speciﬁc primers and
(n = 3) in expression levels compared to the PDL 30 (A and B) or H2O2 minus control (C a
chamber slides and the subcellular distribution of PLD2 (rhodamine) was assessed by im
nuclei (blue). (F) IMR-90 cells at PDL 32 and 53 were collected, and PLD activity was dedetected in the cytoplasm and the nucleus of proliferating IMR-
90 cells, PLD2 expression was markedly reduced in senescent
IMR-90 cells. The subcellular distribution of PLD2 remained essen-
tially unchanged during senescence (Fig. 1E). We examined
whether PLD catalytic activity was modulated during replicative
senescence. PLD activity decreased by 25% in senescent cells com-
pared to proliferating cells (Fig. 1F). Taken together, these results
indicate that PLD is downregulated in IMR-90 cells during replica-
tive as well as premature senescence.
3.2. Downregulation of PLD2 induces senescence through
a p53–p21Cip1/WAF1 pathway
To investigate the role of PLD2 in cellular senescence, we down-
regulated PLD2 using siRNA in proliferating IMR-90 cells (PDL 32)
and found an increased rate of SA-b-gal staining in proliferating
cells, compared with the control cells (Fig. 2A). Similarly, the accu-
mulation of p53 and p21Cip1/WAF1 proteins was observed in cells
treated with PLD2 siRNA, in comparison with the controls
(Fig. 2B). To examine the role of p53 and p21Cip1/WAF1 in senescence
induced by PLD2 downregulation, we used sublines of the human
colon cancer cell line, HCT116, in which the p53 or p21Cip1/WAF1
genes are inactivated by homozygous knockout [12,18,19]. In the
wild-type HCT116 cells, signiﬁcant increase in SA-b-gal activity
in response to PLD2 knockdown was observed. However,
p53- and p21Cip1/WAF1-negative cells did not show senescence,
demonstrating that p53 and p21Cip1/WAF1 are required for the
PLD2 knockdown-mediated induction of senescence (Fig. 2C).
When the protein levels of p53 and p21Cip1/WAF1 were determined
by Western blot, the expression of p53 was found to be upregu-
lated in both the wild type and p21Cip1/WAF1/ cells treated with
PLD2 siRNA, but not in p53/ cells. The expression of p21Cip1/A) After serial passaging, IMR-90 cells at PDL of 30 and 53 were obtained. Cells were
on 2. Representative images were obtained at 20 magniﬁcation (left panel). Cells
sualized by Western blotting with the appropriate antibodies (right panel). b-actin
ribed using PLD1- or PLD2-speciﬁc primers and reverse transcriptase. PCR products
ultiple concentrations of H2O2 at 37 C for 2 h. After removing H2O2 by changing the
bromo-4-chloro-3-indolyl b-D-galactoside (left panel). Cells were lysed, subjected to
ing with the appropriate antibodies (right panel). (D) Total RNA was extracted from
reverse transcriptase. Values below each band represent the mean fold differences
nd D), which were assigned a value of 100. (E) IMR-90 cells were seeded onto Nunc
munocytochemical staining. Cells were counterstained with DAPI to visualize the
termined as described in the Section 2.
Fig. 2. Downregulation of PLD2 induces premature senescence through a p53–p21Cip1/WAF1 pathway. (A) IMR-90 cells (PDL 32) were transfected with control or PLD2 siRNA.
5 h after transfection, the medium was changed and the cells were grown for 3 days. Cells were ﬁxed and stained with 5-bromo-4-chloro-3-indolyl b-D-galactoside, after
which the percentage of positively stained cells was measured (upper panel). Data are shown as the mean ± S.E.M. ⁄⁄P < 0.01. Representative images were obtained at 20
magniﬁcation (bottom panels). (B) PLD2 siRNA-treated IMR-90 cells were lysed, electrophoresed on a 10% (w/v) SDS–polyacrylamide gel, and visualized by Western blotting
with the appropriate antibodies. b-actin served as the loading control. Values below each band represent the mean fold differences (n = 3) in expression levels compared to
the PLD2 siRNA negative control, which was assigned a value of 100. (C) Wild-type (WT), p21/, and p53/ HCT116 cells were treated with control or PLD2 siRNA. 5 h after
transfection, the medium was changed and the cells were grown for 3 days. Cells were ﬁxed and stained with 5-bromo-4-chloro-3-indolyl b-D-galactoside, after which the
percentage of positively stained cells was measured (upper panel). Data are shown as the mean ± S.E.M. ⁄⁄P < 0.01. Representative images were obtained at 20magniﬁcation
(bottom panels). (D) siRNA-treated HCT116 cells were lysed, electrophoresed on a 10% (w/v) SDS–polyacrylamide gel, and visualized by Western blotting with the
appropriate antibodies.
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with PLD2 siRNA (Fig. 2D). Taken together, these results indicate
that the activation of p53–p21Cip1/WAF1 pathway acts as a major
mediator of PLD2 knockdown-mediated senescence.
3.3. PLD2 downregulation increases the intracellular ROS in a NADPH
oxidase (NOX)-dependent manner
Since ROS stabilizes p53 [20], we examined whether ROS are
generated in PLD2 knockdown-induced senescent cells by incubat-
ing IMR-90 and HCT116 cells with CM-H2DCFDA or DHE. CM-H2
DCFDA is hydrolyzed to DCFH, which is then oxidized by hydrogen
peroxide to yield the ﬂuorescent DCF [21]. DHE, which is relatively
speciﬁc for the superoxide anion (O2), is oxidized to the ﬂuores-
cent ethidium (ETH) [22]. As shown in Fig. 3A, PLD2 siRNA signif-
icantly increased the production of hydrogen peroxide and
superoxide anion in proliferating IMR-90 (PDL 32) as well as
HCT116 cells, as indicated by the rightward shift in DCF and ETH
ﬂuorescence using ﬂow cytometry. Incubation with N-acetyl-L-cys-
teine (NAC), which is a commonly used scavenger of ROS, appeared
to inhibit the ﬂuorescent signal in the PLD2 siRNA-treated cells.
NOX produces superoxide anion using NADPH as the electron
donor [23]. To conﬁrm the involvement of superoxide anion in
the cellular responses subsequent to PLD2 downregulation, prolif-
erating IMR-90 (PDL 32) and HCT116 cells were incubated with the
NOX inhibitor, apocynin. The presence of apocynin signiﬁcantly
suppressed PLD2 knockdown-induced ROS generation (Fig. 3B).
Since p22phox is a common integral component of the electron-
transport machinery for NOX family enzymes [24], we knockeddown p22phox using siRNA in PLD2-inhibited cells. Transfection of
p22phox siRNA markedly decreased the PLD2 knockdown-mediated
ROS generation (Fig. 3B). When cells were treated with apocynin or
p22phox siRNA alone as a negative control, ROS production
decreased in the cells (Supplementary Fig. 1). To investigate
whether PLD2 inhibition affects the mitochondrial superoxide gen-
eration, we stained proliferating IMR-90 (PDL 32) and HCT116 cells
with MitoSOX Red, which selectively detects superoxide in the
mitochondria of live cells [25]. As shown in Fig. 3C, transfection
with PLD2 siRNA did not induce MitoSOX ﬂuorescence. Next, we
examined whether NAC and apocynin could rescue the cellular
senescence induced by PLD2 downregulation. While treatment
with PLD2 siRNA increased the SA-b-gal activity in IMR-90 (PDL
32) and HCT116 cells, co-treatment with NAC or apocynin resulted
in a decrease in this activity (Fig. 3D). Similarly, co-treatment with
NAC or apocynin caused cells to exhibit an apparently lower
expression of p53 and p21Cip1/WAF1 proteins compared with that
in cells treated with PLD2 siRNA (Fig. 3E). Taken together, these
results indicate that the superoxide anion generated by NOX is
involved in the induction of senescence by PLD2 downregulation.
3.4. CK2a overexpression suppresses PLD2 knockdown-mediated
senescence
We previously showed that the ROS–p53–p21Cip1/WAF1 pathway
acts as an important mediator of CK2 inhibition-induced cellular
senescence [26–28]. Here, we demonstrate that this pathway is
also necessary for PLD2 knockdown-mediated senescence. Thus,
we examined whether CK2 was involved in the senescence induced
Fig. 3. PLD2 downregulation produces ROS via a NOX-dependent pathway in cells. (A and B) IMR-90 (PDL 32) and HCT116 cells were transfected with PLD2 siRNA grown for
2 days in the presence or absence of 10 mM NAC (A) and 10 lM apocynin or p22phox siRNA (B). The cells were then incubated with 5 lM CM-H2DCFDA (upper panels) or DHE
(bottom panels) as described in Section 2. The ﬂuorescence intensity was determined by ﬂow cytometry analysis. The mean ﬂuorescence intensity is shown in the upper-right
corners of the histograms. (C) IMR-90 (PDL 32) and HCT116 cells were transfected with PLD2 siRNA and grown for 4 days. The cells were then incubated with 5 lMMitoSOX
Red as described in Section 2 and the ﬂuorescence intensity was determined by ﬂow cytometry analysis. (D and E) IMR-90 (PDL 32) and HCT116 cells were transfected with
PLD2 siRNA in the presence or absence of 10 mM NAC or 10 lM apocynin and grown for 2 days. (D) Cells were ﬁxed and stained with 5-bromo-4-chloro-3-indolyl
b-D-galactoside as described in Section 2. The percentage of positively stained cells was measured. Values indicate mean ± S.E. Bars that do not share a common letter (a, b, c)
are signiﬁcantly different among the groups at P < 0.05. (E) Cells were lysed, subjected to electrophoresis on a 10% (w/v) SDS–polyacrylamide gel, and visualized by Western
blotting with the appropriate antibodies.
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IMR-90 (PDL 32) and HCT116 cells were transfected with PLD2
siRNA, and a signiﬁcant increase in the SA-b-gal activity was found
in response to PLD2 knock-down, whereas co-transfection of
cells with CK2a resulted in a signiﬁcant decrease in the level of
SA-b-gal staining (Fig. 4A). Similarly, co-treatment of cells
with CK2a evidently suppressed the upregulation of p53 and
p21Cip1/WAF1 (Fig. 4B) as well as the ROS generation (Fig. 4C)
induced by PLD2 downregulation. Taken together, these data dem-
onstrate that elevated CK2a expression can repress senescence
induced by PLD2 downregulation.
3.5. Elevated PLD2 expression suppresses CK2 inhibition-mediated
senescence through increased CK2 activity
We examined whether PLD2 modulates the senescence induced
by CK2 inhibition. IMR-90 (PDL 32) and HCT116 cells were trans-
fected with CK2a siRNA to induce senescence and then stained
for SA-b-gal activity. Consistent with previous reports [26–28],
we observed a signiﬁcant increase in SA-b-gal activity in responseto CK2a knockdown. However, co-transfection of cells with
wild-type PLD2 resulted in a signiﬁcant decrease in the level of
SA-b-gal staining. In contrast, overexpression of the catalytically
inactive mutant of PLD2 (K758R) did not affect SA-b-gal activity
in cells (Fig. 5A). To further characterize the relationship between
PLD activity and suppression of CK2 inhibition-induced senes-
cence, PLD activity was assessed. Fig. 5B shows that CK2a knock-
down resulted in a decrease in PLD activity that could be
recovered by wild-type PLD2. The expression of p53 and p21Cip1/
WAF1 was upregulated in cells treated with CK2a siRNA, whereas
co-treatment with the wild-type PLD2, but not the K758R mutant,
reduced the expression of both p53 and p21Cip1/WAF1 (Fig. 5C). Co-
treatment with wild-type PLD2, but not the K758R mutant, also
inhibited ROS generation induced by CK2a knockdown (Fig. 5D).
Taken together, these data demonstrate that elevated PLD2 expres-
sion can repress senescence induced by CK2 inhibition, and that
the catalytic activity of PLD2 is necessary for this event.
Previously, it has been demonstrated that PLD is activated and
phosphorylated by CK2 in U87 astroglioma cells [29]. Based on
our observation that PLD2 can inhibit CK2 inhibition-mediated
Fig. 4. CK2a overexpression suppresses PLD2 knockdown-mediated senescence in cells. IMR-90 (PDL 32) and HCT116 cells were transfected with PLD2 siRNA in the presence
or absence of pcDNA3.1-CK2a and grown for 2 days. (A) Cells were ﬁxed and stained with 5-bromo-4-chloro-3-indolyl b-D-galactoside, after which the percentage of
positively stained cells was measured (upper panels). Data are shown as the mean ± S.E.M. Bars that do not share a common letter (a, b, c) are signiﬁcantly different among
the groups at P < 0.05. Representative images were obtained at 20magniﬁcation (bottom panels). (B) Cells were lysed and subjected to electrophoresis on a 10% (w/v) SDS–
polyacrylamide gel. Protein bands were then visualized by Western blotting with the appropriate antibodies. HA, hemagglutinin. (C) Cells were incubated with CM-H2DCFDA
or DHE as described in Section 2 and the ﬂuorescence intensity was determined by ﬂow cytometry analysis.
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ity of CK2 in HCT116 and IMR-90 cells. The CK2 activity was
assessed using [c-32P]ATP and the synthetic peptide substrate
RRREEETEEE. As shown in Fig. 5E, the phosphotransferase activity
of CK2 was approximately 25% higher in PLD2-overexpressing
HCT116 and IMR-90 cells. In contrast, PLD2 knockdown reduced
the activity of CK2 by 20% compared to the control cells. Neverthe-
less, the protein levels of CK2a did not change upon PLD2 overex-
pression or knockdown. Collectively, these data demonstrate that
PLD2 can upregulate CK2 activity at the post-translational level.
4. Discussion
The results of the present study demonstrate that the expres-
sion of PLD1 and PLD2 decreases during replicative as well as pre-
mature senescence in IMR-90 cells. The apparent inverse
relationship between the expression level of PLD1 and PLD2 and
the growth of IMR-90 cells suggests that the decrease in PLD activ-
ity may be tightly coupled to the senescence process. In addition,
our results demonstrate that the senescence-associated decrease
in PLD expression is mainly regulated at the transcriptional level.
Since PLD2 exhibited a higher basal level of cellular activity than
PLD1 [1,2], we focused on the role of PLD2 in senescence in this
study. The notion that downregulation of PLD may be linked to
senescence is supported by the observation that exogenously
added PLD2 siRNA could induce the senescent phenotype in IMR-
90 cells. How can PLD downregulation induce cellular senescence?
In the present study, we show that the expression of both p53 and
p21Cip1/WAF1 is upregulated in IMR-90 and wild-type HCT116 cells
treated with PLD2 siRNA. In addition, senescence induced by PLD2
downregulation is strongly attenuated in p53/ or p21Cip1/WAF1/
HCT116 cells. Thus, this study demonstrates that the activation ofp53–p21Cip1/WAF1 pathway acts as a major mediator of PLD2 knock-
down-induced senescence.
The tumor suppressor protein p53 is a potent transcription fac-
tor that plays a key role in cell cycle regulation. p53 is activated in
response to a variety of cellular stress signals including DNA dam-
age and triggers cell cycle arrest or apoptosis to prevent cells from
undergoing transformation [20]. The present study indicates a pos-
sible mechanism by which PLD2 downregulation can stabilize and/
or activate p53. First, PLD2 downregulation induced DCF and ETH
signals, which were blocked by the NAC treatment, indicating the
cellular production of hydrogen peroxide and superoxide anion.
Second, apocynin and p22phox siRNA almost completely abolished
the PLD2 knockdown-induced increase in ROS. Finally, NAC and
apocynin successfully rescued the p53 stabilization and senescence
induced by PLD2 downregulation. Thus, these ﬁndings indicate
that NOX-dependent superoxide anion production is a major
upstream contributor of the PLD2 knockdown-mediated senes-
cence signaling cascade.
CK2 is known to be a second messenger-independent serine/
threonine kinase. The holoenzyme of CK2 is a heterotetramer com-
posed of two catalytic (a) and two regulatory (b) subunits [30].
Dysregulated CK2 activity has been implicated in the development
and progression of a variety of tumor or leukemic cells [31–33]. In
addition, CK2 reportedly phosphorylates caspase substrates, pre-
venting apoptosis [34]. These observations suggest that CK2 plays
a pivotal role in diverse cellular processes such as cell growth, pro-
liferation, and apoptosis. We have previously shown that CK2 inhi-
bition induces cellular senescence via the ROS–p53–p21Cip1/WAF1
pathway [26–28]. Our results signify that enhanced CK2 activity
signiﬁcantly suppresses PLD2 knockdown-mediated senescence
and ROS production in IMR-90 and HCT116 cells. In addition, ele-
vated PLD2 expression also suppresses senescence as well as ROS
Fig. 5. Elevated PLD2 expression suppresses senescence through the increase of CK2 activity. (A–D) IMR-90 cells (PDL 32) and HCT116 cells were co-transfected with
wild-type (WT) or mutant (K758R, KR) PLD2 in the presence of CK2a siRNA and grown for 2 days. (A) Cells were ﬁxed and stained with 5-bromo-4-chloro-3-indolyl
b-D-galactoside, and the percentage of positively stained cells was measured. (B) Cells were collected, and PLD activity was determined as described in the Section 2. (C) Cells
were lysed, electrophoresed on a 10% (w/v) SDS–polyacrylamide gel, and visualized by Western blotting with the appropriate antibodies. (D) Cells were incubated with CM-
H2DCFDA (upper panels) or DHE (bottom panels) as described in Section 2 and the ﬂuorescence intensity was determined by ﬂow cytometry analysis. (E) IMR-90 (PDL 33) and
HCT116 cells were transfected with PLD2 siRNA or pcDNA3.1-PLD2 and grown for 2 days. Cell lysates were visualized by Western blotting with the appropriate antibodies
(upper panels) and assessed for CK2 activity (bottom panels). Data are shown as the mean ± S.E.M. Bars that do not share a common letter (a, b, c or A, B, C) are signiﬁcantly
different among the groups at P < 0.05. (F) Putative model illustrating PLD2 knockdown-mediated cellular senescence. PLD2 downregulation results in the activation of the
p53–p21Cip1/WAF1-dependent cellular senescence pathway through ROS generation, which is mediated via CK2 inhibition. CK2 stimulates PLD2 activity in human cells [29].
Y.-H. Lee, Y.-S. Bae / FEBS Letters 588 (2014) 3251–3258 3257generation induced by CK2 inhibition. Furthermore, overexpres-
sion of PLD2 was found to stimulate the catalytic activity of CK2,
whereas CK2 activity decreased in response to PLD2 knockdown.
Collectively, the present study demonstrates that downregulation
of PLD2 promotes senescence through a pathway identical to that
of the CK2 inhibition-mediated senescence (Fig. 5F). In a previous
study, CK2 was shown to phosphorylate and activate PLD2 in
human cells [29]. PKC has been previously reported to enhance
CK2 activity through CK2b phosphorylation in vitro [35]. Our
recent data suggested that PLD2 stimulated PKC catalytic activity,
which was responsive for CK2a phosphorylation and subsequent
stimulation of CK2 activity. Furthermore, PKC-speciﬁc activator
stimulated CK2 activity in cells, whereas PKC inhibitor suppressed
the activity (Lee and Bae, manuscript in preparation).
Increasing evidence over the last few decades has implicated
cellular senescence as an important anti-cancer defense mecha-
nism. Thus, understanding the underlying mechanisms of prema-
ture senescence may contribute to the development of improved
and effective cancer treatments. In summary, this study has dem-
onstrated a new senescence signaling pathway that speciﬁcally
involves PLD2. PLD2 downregulation decreases CK2 activity, lead-
ing to NOX-dependent ROS generation with subsequent activation
of p53 and p21Cip1/WAF1. These novel observations will provide abetter understanding of cellular senescence as well as novel diag-
nostic and therapeutic options for the treatment of various tumors.
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